Aghamir Seyed Mohammad Kazem, Mohseni Mohammd Ghasem, Arasteh Saeed
Department of Urology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Urol J. 2007 Winter;4(1):18-23.
The aim of this study was to examine the efficacy and safety of intravesical Bacillus Calmette-Guerin (BCG) in the treatment of refractory interstitial cystitis (IC).
Thirteen patients with refractory IC were enrolled in the study. They were scheduled to receive 6 weekly courses of treatment with intravesical BCG. Variables including the frequency, nocturia, urgency, pelvic pain, dyspareunia, dysuria, IC symptom index, IC problem index, and average voided volume were assessed every 6 months after the BCG therapy.
Thirteen patients received the complete course of intravesical BCG therapy. Twenty-four months after the treatment a mean improvement of 51.9% was seen in frequency (P=.001), 43.2% in nocturia (P=.002), 28.7% in urgency (P=.004), 43.1% in pelvic pain (P=.001), 58.3% in dyspareunia (P=.003), 6.5% in dysuria (P=.16), 57.7% in the O'Leary-Sant IC symptom index (P=.001), and 61.8% in the O'Leary-Sant IC problem index (P=.001) scores. A significant improvement was seen in the mean average voided volume at the 24th follow-up month (89.5%; P=.001).
Intravesical BCG is a relatively effective treatment in patients with refractory IC. Its efficacy seems to be modest and lasts for at least 24 months in majority of the patients. It is also safe and well tolerated.
本研究的目的是检验膀胱内灌注卡介苗（BCG）治疗难治性间质性膀胱炎（IC）的疗效和安全性。
13例难治性IC患者纳入本研究。他们计划接受6周的膀胱内BCG治疗疗程。在BCG治疗后每6个月评估包括尿频、夜尿、尿急、盆腔疼痛、性交困难、排尿困难、IC症状指数、IC问题指数和平均排尿量等变量。
13例患者接受了完整疗程的膀胱内BCG治疗。治疗24个月后，尿频平均改善51.9%（P = .001），夜尿平均改善43.2%（P = .002），尿急平均改善28.7%（P = .004），盆腔疼痛平均改善43.1%（P = .001），性交困难平均改善58.3%（P = .003），排尿困难平均改善6.5%（P = .16），O'Leary-Sant IC症状指数平均改善57.7%（P = .001），O'Leary-Sant IC问题指数评分平均改善61.8%（P = .001）。在第24个月随访时平均排尿量有显著改善（89.5%；P = .001）。
膀胱内灌注BCG对难治性IC患者是一种相对有效的治疗方法。其疗效似乎适中，且在大多数患者中至少持续24个月。它也是安全的且耐受性良好。
